On March 2, 2026 the U.S. Food and Drug Administration accepted the New Drug Application for rusfertide and granted the drug priority review, setting a Prescription Drug User Fee Act target date in the third quarter of 2026.
Rusfertide is a first‑in‑class hepcidin mimetic peptide that targets the iron‑regulation pathway in polycythemia vera. The drug has earned Breakthrough Therapy, Orphan Drug, and Fast Track designations, and its approval was supported by positive Phase III VERIFY data that showed superior hematocrit control, a marked reduction in phlebotomy requirements, and improved patient‑reported outcomes.
The partnership between Takeda and Protagonist, established in January 2024, gives Takeda the lead on U.S. regulatory strategy while Protagonist retains a 50/50 profit‑and‑loss share option for U.S. commercialization. The collaboration reflects Takeda’s strategy to strengthen its late‑stage pipeline and offset the impact of generic competition for products such as Vyvanse.
"There is an urgent need for innovative treatment options in poly‑cythemia vera, where patients currently face limited therapeutic choices to control their hematocrit and significant symptom burden. The FDA's acceptance of our NDA brings us closer to potentially offering a first‑in‑class therapy that could meaningfully improve clinical outcomes and quality of life. This milestone is a reflection of our successful partnership with Protagonist and Takeda's unwavering commitment to advancing innovative treatments in hematologic cancers where significant unmet needs persist," said Andy Plump, president of R&D at Takeda.
"Rusfertide exemplifies Protagonist's end‑to‑end expertise, from exploring a novel hepcidin mimetic mechanism to address unmet needs in poly‑cythemia vera to discovering the peptide and driving its clinical development through NDA filing. We are very pleased with the FDA granting rusfertide Priority Review and look forward to its potential approval in 2026. We have identified a great partner in Takeda as rusfertide progresses toward this milestone, thereby bringing a successful closure to our more than decade‑long journey from concept‑to‑commercialization," said Dinesh V. Patel, president and CEO of Protagonist.
The FDA acceptance and priority review position rusfertide as a potential blockbuster in the rare‑disease hematology space and provide Takeda with a new revenue stream that aligns with its strategy to counter the Vyvanse headwind. The milestone also signals strong clinical evidence and regulatory confidence, potentially accelerating market entry and enhancing Takeda’s late‑stage pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.